NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-MH-17-009 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-021 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-020 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-17-131 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to support lead optimization and preclinical development of new therapies for diseases within the mission of the NIDDK with the STTR program. STTR Phase I projects under this FOA support preliminary steps in the process for lead optimization or preclinical development of therapeutics. STTR Phase II supports lead optimization and preclinical development of lead candidates, and projects must be sufficiently advanced such that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of a STTR Phase II or IIB project. Applications are expected to have defined Milestones and Timelines detailing how the project will move forward with identified key Go / No Go decision points.
Funding Opportunity PA-17-130 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to support lead optimization and preclinical development of new therapies for diseases within the mission of the NIDDK with the SBIR program. SBIR Phase I projects under this FOA supportpreliminary steps in the process for lead optimization or preclinical development of therapeutics. SBIR Phase II supports lead optimization and preclinical development of lead candidates, and projects must be sufficiently advanced such that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of a SBIR Phase II or IIB project. Applications are expected to have defined Milestones and Timelines detailing how the project will move forward with identified key Go / No Go decision points.
Notice NOT-OD-17-040 from the NIH Guide for Grants and Contracts
Notice NOT-TW-17-003 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-022 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-129 from the NIH Guide for Grants and Contracts. This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those tools in prospective multisite clinical trials in order to test tool performance and to demonstrate that the tool can be integrated into clinical workflow with a minimum of disruption.
Funding Opportunity PAR-17-128 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials.
Funding Opportunity RFA-NS-17-020 from the NIH Guide for Grants and Contracts. The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose outstanding records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PIs recent NINDS support (Part 2, Section II) This greater funding stability will provide investigators with increased freedom and flexibility which may allow them to be more adventurous in their research, to take greater risks, to embark upon research that breaks new ground, to undertake research projects that require a longer timeframe, and/or to extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission (http://www.ninds.nih.gov/about_ninds/mission.htm). Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center will not be considered through this program.
Notice NOT-OD-17-036 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-039 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-038 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-037 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-127 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to invite pilot/feasibility projects for: 1) descriptive studies to identify putative juvenile protective factors, 2) experimental studies to test hypotheses about their effects on aging and 3) translational studies to characterize potential beneficial and adverse effects of maintaining or modulating the level of juvenile protective factors in adult life. Juvenile protective factors (JPFs), intrinsic to an immature organism, help to maintain or enhance certain physiological functions across all or some stages of postnatal development (i.e., segment of the life span between birth and sexual maturity), but diminish or disappear as the organism transitions from one maturational stage to the next. The loss or diminution of JPFs after a given stage of postnatal development or at time of sexual maturity may contribute to the onset of deleterious aging changes (e.g., compromised stem cell function and reparative capacity) across adulthood. This FOA is uniquely focused on animal and clinical studies which involve comparisons between juvenile versus adult states or between stages of postnatal development to identify putative JPFs and their effects on aging. Pilot studies which involve comparisons between young and old adults will not be supported by this FOA.
Funding Opportunity PAR-17-126 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to invite: 1) descriptive studies to identify putative juvenile protective factors, 2) experimental studies to test hypotheses about their effects on aging and 3) translational studies to characterize potential beneficial and adverse effects of maintaining or modulating the level of juvenile protective factors in adult life. Juvenile protective factors (JPFs), intrinsic to an immature organism, help to maintain or enhance certain physiological functions across all or some stages of postnatal development (i.e., segment of the life span between birth and sexual maturity), but diminish or disappear as the organism transitions from one maturational stage to the next. The loss or diminution of JPFs after a given stage of postnatal development or at time of sexual maturity may contribute to the onset of deleterious aging changes (e.g., compromised stem cell function and reparative capacity) across adulthood. This FOA is uniquely focused on animal and clinical studies which involve comparisons between juvenile versus adult states or between stages of postnatal development to identify putative JPFs and their effects on aging. Studies which involve comparisons between young and old adults will not be supported by this FOA.
Funding Opportunity PAR-17-124 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis. This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application need not have extensive background material or preliminary information.
Funding Opportunity PAR-17-125 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.
Funding Opportunity RFA-HL-18-003 from the NIH Guide for Grants and Contracts. The primary objective of the work to be supported by this funding opportunity is to understand the mechanisms by which female sex hormones and sex hormone-based therapies can increase the risk of venous and arterial thromboembolism in pre-menopausal women. Understanding the basic physiopathology of how sex hormones may induce or add to the pre-existing risk of thrombosis will strengthen our understanding of the mechanisms underlying thrombus formation in relevant clinical situations such as peripartum or in women using contraceptives or undergoing in vitro fertilization. Such research may help identify women at higher thrombotic risk and thus help guide their clinical care. It could also lead to the identification of potential new therapeutics to prevent thrombus formation. The FOA purpose does not include research on thromboembolism related comorbidities in post-menopausal women.